tbuckley/cabot-search huggingface dataset:
Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in Young Children
Authors: David M. Fleischer, Terri F. Brown-Whitehorn, Stacie M. Jones, Edwin Kim, Kari C. Nadeau, Julie Wang, Robert A. Wood, Anna H. Nowak-Wegrzyn, Arthur Jaffrelot, Todd David Green, A. Wesley Burks
Journal: Journal of Allergy and Clinical Immunology (2019)
Single Cell RNA-Seq Characterises Pre-Leukemic Transformation Driven By CEBPA N321D in the Hoxb8-FL Cell Line
Authors: Moosa Qureshi, Fernando Calero-Nieto, Iwo Kucinski, Sarah Kinston, George Giotopoulos, Dean Pask, Rebecca Hannah, Evangelia Diamanti, Xiaonan Wang, Reiner Schulte, Chiara Cossetti, Anthony R Green, Brian J.P Huntly, Berthold Gottgens
Journal: Blood (2018)
GSH-sensitive Pt(IV) prodrug-loaded phase-transitional nanoparticles with a hybrid lipid-polymer shell for precise theranostics against ovarian cancer
Authors: Hui Huang, Yang Dong, Yanhua Zhang, Dan Ru, Zhihua Wu, Jiali Zhang, Ming Shen, Yourong Duan, Ying Sun
Journal: Theranostics (2019)

: Platinum (II) (Pt(II))-based anticancer drugs dominate the chemotherapy field of ovarian cancer. However, the patient's quality of life has severely limited owing to dose-limiting toxicities and the advanced disease at the time of diagnosis. Multifunctional tumor-targeted nanosized ultrasound contrast agents (glutathione (GSH)-sensitive platinum (IV) (Pt(IV)) prodrug-loaded phase-transitional nanoparticles, Pt(IV) NP-cRGD) were developed for precise theranostics against ovarian cancer.
Abstract 11378: Dynamic Secretion Analysis by Novel Microfluidic Platform mFLISA Reveal Contextual and Precise Paracrine Signatures Preventing Cardiac Injury
Authors: Kshitiz Kshitiz, David D Ellison, Yasir Suhail, Junaid Afzal, Laura Woo, Andre Levchenko
Journal: Circulation (2016)

It is now increasingly recognized that a variety of stem cells offer therapeutic benefit to injured tissues via paracrine signaling. Paracrine signaling via secreted ligands is an important mediator of cell function. It has been a challenge to precisely measure cellular secretions in relevant physiological contexts. Here we introduce a high throughput platform combining protein microprinting and microfluidics, μFLISA, to directly measure cellular secretion and estimate the kinetics for the detected secretome (Fig. 1A). μFLISA design allows for precise evaluation of the diffusion of secreted molecules, as well as retroactive determination of the dynamics of secretion without time course measurements (Fig. 1B). Furthermore, its unique architecture facilitates precise control over measurement timings in response to arbitrary biological stimuli. Using μFLISA we estimated the secretion dynamics for different constituents of the secretome for bone marrow derived stem cells (BMSCs), reported to provide benefit in response to myocardial injury. We found that secretory kinetics are highly contextual and are regulated in response to individual factors present in myocardial infarction, e.g. hypoxia (Fig. 1B). Using an in vitro model of ischemia reperfusion with human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs), we estimated the absolute concentration of BMSC secretome in response to reperfusion insult (Fig. 1C). We provide strong evidence for the hypothesis that secretion by stem cells is contextual, is regulated by injury signals from myocardium, and that both the absolute concentration and dynamics of paracrine signaling determines cardioprotection. Precise estimation of concentration and kinetics of BMSC secretome will facilitate our understanding of the molecular mechanisms involved in stem cell mediated cardioprotection, as well as pave the way towards a cell-less therapy by mimicking the paracrine signaling by stem cells.
Abstract P3-03-08: Not presented
Authors: Y Liang, X Chen, W Zhan, Y Zhu, J Wu, O Huang, J He, L Zhu, Y Li, W Chen, K Shen
Journal: Cancer Research (2019)

Abstract This abstract was not presented at the conference. Citation Format: Liang Y, Chen X, Zhan W, Zhu Y, Wu J, Huang O, He J, Zhu L, Li Y, Chen W, Shen K. Not presented [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-03-08.
Pregnancy outcomes after maternal Zika virus infection in a non-endemic region: prospective cohort study
Authors: C. Rodó, A. Suy, E. Sulleiro, A. Soriano-Arandes, N. Maiz, I. García-Ruiz, S. Arévalo, A. Rando, A. Anton, É. Vázquez Méndez, M. Garrido, A. Frick, C. Rodrigo, T. Pumarola, E. Carreras
Journal: Clinical Microbiology and Infection (2019)
Phenotypic differences between African American and Caucasian children with food allergy in the FORWARD study
Authors: Mary C. Tobin, Mahboobeh Mahdavinia, Susan R. Fox, Aame B. Andy-Nweye, Iman A. Abdikarim, Hemant P. Sharma, Jamie L. Fierstein, Jialing Jiang, Pamela J. Newmark, Crystal J. Johnson, Lucy A. Bilaver, Alexandria Bozen, Avneet S. Chadha, Jacqueline A. Pongracic, Perry A. Catlin, Amal H. Assa'ad, Ruchi S. Gupta
Journal: Journal of Allergy and Clinical Immunology (2019)
Practice‐based differences in paediatric discoid lupus erythematosus
Authors: L.M. Arkin, K. Buhr, H. Brandling‐Bennett, Y. Chiu, B. Chong, M. Curran, R. Hunt, A.S. Paller, V.P. Werth, M. Klein‐Gitelman, E. von Scheven, K. Ardalan
Journal: British Journal of Dermatology (2019)

Children with discoid lupus erythematosus (DLE) are at risk for disfigurement and progression to systemic lupus erythematosus (SLE). Consensus is lacking regarding optimal care for children with DLE. The aim of this study was to compare practice patterns among paediatric dermatologists/rheumatologists treating paediatric DLE. An online survey was sent to 292 paediatric rheumatologists in the Childhood Arthritis and Rheumatology Research Alliance and 200 paediatric dermatologists in the Pediatric Dermatology Research Alliance. Consensus was defined as ≥ 70% agreement. Survey response rates were 38% (76 of 200) for dermatology and 21% (60 of 292) for rheumatology. Both specialties agreed that screening labs should include complete blood counts with differential, urinalysis, complement levels, erythrocyte sedimentation rate, antinuclear antibody and other autoantibodies, hepatic function and renal function/electrolytes. Both specialties agreed that arthritis or nephritis should prompt intensified evaluation for SLE. No other patient features achieved consensus as disease‐modifying risk factors. Hydroxychloroquine was agreed upon as first‐line systemic therapy, but consensus was lacking for second‐ or third‐line treatment. We found few areas of consensus and significant practice differences between paediatric dermatologists and rheumatologists treating DLE. Knowledge gaps include risk factors for SLE, optimal screening and treatment of refractory skin disease.
Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
Authors: Arnaud Jeanson, Pascale Tomasini, Maxime Souquet-Bressand, Nicolas Brandone, Mohamed Boucekine, Mathieu Grangeon, Solène Chaleat, Natalyia Khobta, Julie Milia, Laurent Mhanna, Laurent Greillier, Julie Biemar, Isabelle Nanni, L’houcine Ouafik, Stéphane Garcia, Julien Mazières, Fabrice Barlesi, Céline Mascaux
Journal: Journal of Thoracic Oncology (2019)
From Bone Marrow to Mobilized Peripheral Blood Stem Cells: The Circuitous Path to Clinical Gene Therapy for Fanconi Anemia
Authors: Pamela S Becker, Jennifer Adair, Grace Choi, Anne Lee, Ann Woolfrey, Lauri S Burroughs, Kanwaldeep K. Mallhi, Amy E. Geddis, Hans-Peter Kiem
Journal: Blood (2018)
Residual Disease after Neoadjuvant Therapy — Developing Drugs for High-Risk Early Breast Cancer
Authors: Tatiana M. Prowell, Julia A. Beaver, Richard Pazdur
Journal: New England Journal of Medicine (2019)

Despite ongoing questions about whether pathological complete response rates can identify beneficial agents in early breast cancer, trials are under way. The KATHERINE trial should prompt study of other strategies for introducing new agents into breast cancer treatment.
Genetic variations within the CD40L immune stimulating gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab: Data from FIRE-3 and TRIBE.
Authors: Martin D. Berger, Sebastian Stintzing, Volker Heinemann, Shu Cao, Yuji Miyamoto, Mitsukuni Suenaga, Diana L. Hanna, Shivani Soni, Alberto Puccini, Ryuma Tokunaga, Madiha Naseem, Francesca Battaglin, Wu Zhang, Chiara Cremolini, Alfredo Falcone, Fotios Loupakis, Heinz-Josef Lenz
Journal: Journal of Clinical Oncology (2019)

558 Background: The introduction of immunotherapy has significantly improved outcome in various tumors. Immune stimulating proteins exert an anti-tumor effect mainly through enhancing T-cell mediated immune response. Additionally, preliminary data suggest a major role of immune stimulating proteins in modulating angiogenesis. We therefore hypothesize that variations in genes involved in the immune activation pathway may predict outcome in pts with mCRC treated with first-line FOLFIRI/ bevacizumab (bev). Methods: The impact of 4 functional SNPs within the CD40L, Light, OX40L and ICOS genes on outcome was evaluated in 322 pts with mCRC treated with first-line FOLFIRI/bev in two randomized phase III trials. We used TRIBE as a discovery (n = 215) and FIRE-3 as a validation set (n = 107). One hundred twenty-nine pts treated with FOLFIRI/cetuximab (cet) served as a control cohort (FIRE-3). OncoArray, a custom array manufactured by Illumina was used for data extraction. Genomic DNA was extracted from blood. Results: Baseline characteristics: FOLFIRI/bev, discovery set (TRIBE), median PFS/OS/FU 9.7/26.2/48.9 mo; FOLFIRI/bev, validation set (FIRE-3), PFS/OS/FU 11.5/32.4/71.1 mo; FOLFIRI/cet, control set (FIRE-3) PFS/OS/FU 12.8//23.9/70.7 mo. The CD40L rs1126535 SNP showed significant association with OS. Pts in the discovery cohort harboring any T allele and treated with FOLFIRI/bev had a longer median OS compared to C/C carriers (27.9 vs. 20.0 mo) in both univariate (HR 1.83, 95% CI 1.19-2.81, p = 0.005) and multivariate analyses (HR 1.62, 95% CI 1.03-2.56, p = 0.038). Similarly, any T allele carriers in the validation cohort had a significantly longer median OS than those harboring a C/C genotype (40 vs. 19.0 mo) in the multivariate analysis (HR 2.80, 95% CI 1.05-7.50, p = 0.040). However, this association could not be shown in pts receiving FOLFIRI/cet (HR 0.60, 95% CI, 0.18-1.94, p = 0.38). Conclusions: We show for the first time that the CD40L polymorphism rs1126535 might serve as a predictive marker in pts with mCRC treated with FOLFIRI/bev. Targeting CD40L might be promising to further improve treatment against mCRC and to overcome resistance to anti-angiogenic therapy.
Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Myelodysplastic Syndrome in Adolescent and Young Adult Patients
Authors: Yoshimitsu Shimomura, Masahiko Hara, Takaaki Konuma, Hidehiro Itonaga, Kazuteru Ohashi, Yukiyasu Ozawa, Tetsuya Eto, Naoyuki Uchida, Takehiko Mori, Junji Tanaka, Takahiro Fukuda, Yoshiko Atsuta, Takayuki Ishikawa, Ken Ishiyama
Journal: Blood (2018)
Abstract 16000: Erbb2: A Target of Microrna-7 Regulates Cardiac Remodeling
Authors: Manveen Gupta, Sathyamangla V Naga Prasad
Journal: Circulation (2013)

microRNAs (miRNAs) are tiny regulatory molecules implicated in diverse aspects of cardiac function including pathological signaling that results in deleterious cardiac remodeling transitioning to dilated cardiomyopathy (DCM). Our previous comprehensive genome-wide miRNA-microarray on end stage human DCM samples identified alterations in miRNA-7 in addition to the other well described miRNAs Through a combination of bioinformatics and proteomics approach, we identified tyrosine kinase receptor ERBB2, a member of the epidermal growth factor receptor (EGFR) family as one of the major targets of miRNA-7 which was validated by using different cell lines stably overexpressing miRNA-7. Since ERBB2 is thought to be critical in cardiac remodeling following stress, we hypothesized that downregulation of miRNA-7 would upregulate critical molecules including ERBB2 to overcome the increases in mechanical load with acute and chronic cardiac stress. Consistently, we find reciprocal relationship between miRNA-7 and ERBB2...
Impact of t(11;14) on the Outcome of Autologous Transplantation in Multiple Myeloma: A Matched-Pair Analysis
Authors: Neeraj Y Saini, Ankur Varma, Junsheng Ma, Denái R. Milton, Romil Patel, Omar Hasan, Qaiser Bashir, Yago Nieto, Akash Mukherjee, Ruby Delgado, Gabriela Rondon, Uday Popat, Chitra Hosing, Partow Kebriaei, Amin M. Alousi, Sairah Ahmed, Rohtesh S. Mehta, Stefan O. Ciurea, Issa F. Khouri, Elizabeth J. Shpall, Donna M. Weber, Sheeba K. Thomas, Hans C. Lee, Elisabet E. Manasanch, Krina K. Patel, Robert Z Orlowski, Richard E Champlin, Muzaffar H. Qazilbash
Journal: Blood (2018)
Abstract 17006: Mechanical Aortic Valve Replacement is Associated With Superior Long Term Survival but Equivalent Cardiovascular Mortality Compared to the Ross Operation, at the Cost of an Increased Risk of Hospital Readmissions for Cardiac and Bleeding Causes
Authors: Nicola Vistarini, Dimitri Kalavrouziotis, Jean Perron, Francois Dagenais, Eric Dumont, Pierre Voisine, Siamak Mohammadi
Journal: Circulation (2016)

Introduction: The Ross operation is an attractive alternative to mechanical aortic valve replacement in young adults. The main potential advantages are: no need of anticoagulation, better quality o...
The Prognostic Value of TP53 Mutations Depends on Clinical Backgrounds in Pediatric Patients with Acute Lymphoblastic Leukemia
Authors: Hiroo Ueno, Kenichi Yoshida, Yusuke Shiozawa, Yasuhito Nannya, Yuka Iijima-Yamashita, Nobutaka Kiyokawa, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Tomoya Isobe, Masafumi Seki, Shunsuke Kimura, Hideki Makishima, Nobuyuki Kakiuchi, Keisuke Kataoka, Tetsuichi Yoshizato, Hiroyuki Tsukamoto, Dai Nishijima, Takao Deguchi, Kentaro Ohki, Atsushi Sato, Hiroyuki Takahashi, Yoshiko Hashii, Sadao Tokimasa, Junichi Hara, Yoshiyuki Kosaka, Koji Kato, Takeshi Inukai, Junko Takita, Toshihiko Imamura, Satoru Miyano, Atsushi Manabe, Keizo Horibe, Seishi Ogawa, Masashi Sanada
Journal: Blood (2018)
Nivolumab for Heavily Pretreated Relapsed/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain (Spanish Group of Lymphoma and Bone Marrow Transplantation, GELTAMO)
Authors: Carmen Martinez, Cecilia Carpio, Inmaculada Heras, Eduardo Ríos Herranz, Joan Buch, Antonio Gutierrez, Samuel Romero, Izaskun Ceberio, Irene Garcia-Garcia, Antonia Rodriguez Izquierdo, Rosalia Alonso, Joan Bargay, Cristina Barrenetxea Lekue, Narvaez Javier, Manuel Espeso de Haro, Luis Palomera, Ramon García-Sanz
Journal: Blood (2018)
A Multimaterial Microphysiological Platform Enabled by Rapid Casting of Elastic Microwires
Authors: Yimu Zhao, Erika Yan Wang, Locke Huyer Davenport, Yin Liao, Keith Yeager, Gordana Vunjak‐Novakovic, Milica Radisic, Boyang Zhang
Journal: Advanced Healthcare Materials (2019)

Abstract Due to escalating drug developmental costs and limitations of cardiotoxicity screening, there is an urgent need to develop robust in vitro 3D tissue culture platforms that can both facilitate the culture of human cardiac tissues and provide noninvasive functional readouts predictive of cardiotoxicity in clinical settings. However, such platforms commonly require complex fabrication procedures that are difficult to scale up to high‐throughput testing platforms. Here, innovative multimaterial processing into a scalable and functional platform is proposed in the format of a 96‐well plate. Three classes of materials are integrated into the platform. An array of soft elastic microwires is used both as anchors for tissue formation as well as sensors for recording tissue contraction. Conductive carbon electrodes are embedded into the plate to drive electrical stimulation for tissue maturation and pace tissue contraction during drug testing. The bulk of the device is made of rigid polystyrene plastic to eliminate drug‐absorbing polydimethylsiloxane (PDMS). The platform has higher throughput than the current state‐of‐the‐art devices, at a significantly reduced cost of manufacturing and tissue production.
Prospective Clinical Phase II Results on Treosulfan-Based Conditioning Treatment of 70 Paediatric Patients with Haematological Malignancies
Authors: Krzysztof Kalwak, Peter Bader, Jan Styczynski, Bernd Gruhn, Katharine Patrick, Petr Sedlacek, Daniel Stachel, Karl-Walter Sykora, Selim Corbacioglu, Katarzyna Drabko, Franca Fagioli, Johann Greil, Franco Locatelli, Ingo Müller, Bernhard Kremens, Paul G. Schlegel, Jolanta Gozdzik, Birgit Burkhardt, Monika Mielcarek-Siedziuk, Ajay Vora
Journal: Blood (2018)
Martin Gore: early champion of immunotherapy for cancer
Authors: Chris Mahony
Journal: BMJ (2019)

Around 15 years ago, Martin Gore, who has died from organ failure after a yellow fever vaccination, emerged from a long clinic for patients with advanced melanoma cancer and voiced his frustrations to a junior colleague. After 20 years of such clinics, he was disheartened to be largely prescribing the same drugs as when he was a registrar.

Within a few years, clinical trials led by his unit at the Royal Marsden NHS Foundation and its partner, the Institute of Cancer Research (where he was professor of cancer medicine), had confirmed the efficacy and safety of new immunotherapy treatments that were extending survival times and even curing some patients.

In 2016, when he received a CBE, he spoke of cancer medicine being “on the cusp of a new era of ever more effective therapies.” He admitted then to “some dark days when improvements in treatment for some appeared unobtainable.”

Unusually, Gore was regarded as an international authority on the treatment of three cancers—melanoma, ovarian, and …
Primum non nocere: a call for balance when reporting on CTE
Authors: William Stewart, Kieren Allinson, Safa Al-Sarraj, Corbin Bachmeier, Karen Barlow, Antonio Belli, Mark P Burns, Alan Carson, Fiona Crawford, Kristen Dams-O'Connor, Ramon Diaz-Arrastia, C Edward Dixon, Brian L Edlow, Scott Ferguson, Bruce Fischl, Rebecca D Folkerth, Steve Gentleman, Christopher C Giza, M Sean Grady, Adel Helmy, Mark Herceg, Janice L Holton, David Howell, Peter J Hutchinson, Diego Iacono, Juan E Iglesias, Milos D Ikonomovic, Victoria E Johnson, C Dirk Keene, Julia K Kofler, Vassilis E Koliatsos, Edward B Lee, Harvey Levin, Jonathan Lifshitz, Helen Ling, David J Loane, Seth Love, Andrew IR Maas, Niklas Marklund, Christina L Master, Damien M McElvenny, David F Meaney, David K Menon, Thomas J Montine, Benoit Mouzon, Elliott J Mufson, Joseph O Ojo, Mayumi Prins, Tamas Revesz, Craig W Ritchie, Colin Smith, Richard Sylvester, Cheuk Y Tang, John Q Trojanowski, Kathryn Urankar, Robert Vink, Cheryl Wellington, Elisabeth A Wilde, Lindsay Wilson, Keith Yeates, Douglas H Smith
Journal: The Lancet Neurology (2019)
Residual Clonal Plasma Cells Detected By Flow Cytometry at 10-4level within Autologous Stem Cell Grafts Is Associated with Significantly Less Overall Survival
Authors: Guldane Cengiz Seval, Klara Dalva, Sule Mine Bakanay, Mustafa Merter, Ugur Sahin, Atilla Uslu, Cemaleddin Ozturk, Osman Ilhan, Meral Beksac
Journal: Blood (2018)
Plain tobacco packaging: release of UK court documents will help other countries, says charity
Authors: Clare Dyer
Journal: BMJ (2019)

A US based global organisation that campaigns for tobacco control measures worldwide has won a court order authorising it to make public the documents used in the UK court battle over standardised tobacco packaging.1

The High Court in London has ruled that the documents submitted to the court by tobacco companies challenging the proposed new law, and those from the health secretary defending it, should be released to the Campaign for Tobacco Free Kids (CTFK).

British American Tobacco, Philip Morris, Imperial Tobacco, JT International, and Gallaher had challenged planned UK regulations introducing standardised packaging for tobacco products. They argued that the regulations were unlawful under international, EU, and domestic laws. But the High Court ruled against them in 2015, and appeals were unsuccessful.2

A central plank of the companies’ case, for which they produced expert evidence, was that restrictions on packaging would …
Simultaneous resection of colorectal cancer with synchronous liver metastases: A survey-based analysis.
Authors: Christopher Griffiths, Jessica Bogach, Marko Simunovic, Leyo Ruo, Julie I. Hallet, Pablo Emilio Serrano Aybar
Journal: Journal of Clinical Oncology (2019)

662 Background: Decision to proceed with simultaneous or staged resection in synchronous colorectal cancer liver metastases (CRLM) varies and is usually left to the individual surgeon. We examined practice intentions and barriers to performing simultaneous resection. Methods: We developed and pilot-tested a tailored questionnaire. Members of the Society of Surgical Oncology and the College of Physicians and Surgeons of Ontario operating colorectal cancer were surveyed electronically. Four clinical scenarios of synchronous CRLM determined practice intentions for varying degrees of complexity. Perceived barriers were assessed on a 7-point Likert scale. We compared general and hepatobiliary surgeons’ responses with Mann-Whitney U test for continuous variables and Chi-square test for categorical variables. Results: There were 184/1,335 surgeons (14% response rate), including 50 general and 134 hepatobiliary surgeons. Both were supportive of simultaneous resection, though hepatobiliary surgeons were more so; for minor liver and low complexity colorectal resections (Likert ≥5-7: 83% vs. 98% p&lt;0.001), or for complex colorectal resections (57% vs. 73% p=0.042). Both groups were less supportive of simultaneous resection for complex liver with low complexity (Likert ≥5-7: 26% vs. 24% respectively, p=0.858) or high complexity colorectal resections (11% vs. 7.0% respectively, p=0.436). All perceived that simultaneous resection increases post-operative morbidity (63%), but not mortality (69%). Among hepatobiliary surgeons, the most common barriers for simultaneous resections were comorbidities and extrahepatic disease, whereas general surgeons were more concerned about transfer to another facility. Conclusions: While general and hepatobiliary surgeons are supportive of simultaneous resection, especially for less complex liver resections; support is significantly lower among general surgeons. In addition to complexity of procedures and perceived morbidity, the need for transfer of care appears as a barrier to simultaneous resections. The practice intentions and barriers described are important to identify knowledge gaps, guide future trials, and establish disease care pathways.
Abstract 15190: Comparison of Clinical Effects Following Multi-site versus Single-site CD34+ Cell Injections in Patients With Ischemic Cardiomyopathy
Authors: Gregor Poglajen, Gregor Zemljic, Matjaz Sever, Marko Cukjati, Francois Haddad, Joseph C Wu, Bojan Vrtovec
Journal: Circulation (2014)

Introduction: We investigated the relation between the distribution of transendocardial CD34+ cell injections and clinical response to cell therapy in patients with ischemic cardiomyopathy (ICM). M...